
CAS 1446113-23-0
:Belvarafenib
Description:
Belvarafenib is a small molecule inhibitor primarily targeting the BRAF protein, which is involved in cell signaling pathways that regulate cell growth and division. It is particularly relevant in the context of cancer treatment, especially for tumors with BRAF mutations, such as certain types of melanoma. The compound exhibits selective inhibition of the mutated BRAF kinase, which can lead to reduced tumor cell proliferation and increased apoptosis in cancer cells. Belvarafenib is characterized by its ability to penetrate tissues effectively, which is crucial for its therapeutic efficacy. Additionally, it has been studied in combination with other agents to enhance its anticancer effects and overcome resistance mechanisms. As with many targeted therapies, the pharmacokinetics, safety profile, and potential side effects are important considerations in its clinical application. Ongoing research continues to evaluate its effectiveness and optimize its use in various cancer treatment regimens.
Formula:C23H16ClFN6OS
Synonyms:- 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
- Thieno[3,2-d]pyrimidine-7-carboxamide, 4-amino-N-[1-[(3-chloro-2-fluorophenyl)amino]-6-methyl-5-isoquinolinyl]-
- Belvarafenib
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
4-Amino-N-(1-((3-Chloro-2-Fluorophenyl)Amino)-6-Methylisoquinolin-5-Yl)Thieno[3,2-D]Pyrimidine-7-Carboxamide
CAS:4-Amino-N-(1-((3-Chloro-2-Fluorophenyl)Amino)-6-Methylisoquinolin-5-Yl)Thieno[3,2-D]Pyrimidine-7-CarboxamidePurity:98%Molecular weight:478.93g/molBelvarafenib
CAS:<p>Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF.Cost-effective and quality-assured.</p>Formula:C23H16ClFN6OSPurity:98% - 99.65%Color and Shape:SolidMolecular weight:478.93Belvarafenib
CAS:<p>Belvarafenib is a targeted therapeutic compound categorized as a novel RAF kinase inhibitor. It is sourced through chemical synthesis, designed specifically to target and inhibit aberrant kinase activity in cancer cells. The mode of action involves the selective inhibition of the RAF protein kinases, particularly BRAF, which play a pivotal role in the MAPK/ERK signaling pathway. By interrupting this signal transduction cascade, Belvarafenib effectively halts the proliferation of cancerous cells harboring specific BRAF mutations.</p>Formula:C23H16ClFN6OSPurity:Min. 95%Molecular weight:478.93 g/mol



